Morria’s lead products are first-in-class synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID).
These unique drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage and stimuli. Morria has two lead products (MRX4 for allergic rhinitis and MRX6 for contact dermatitis) are in the clinic and a growing library of additional compounds are in pre-clinical stages.
Double blind placebo controlled Phase IIa studies in contact dermatitis and allergic rhinitis have been successfully completed and showed statistically significant improvement in patients.
Morria aims to advance its clinical and pre-clinical programs to become an innovator in the field of anti-inflammatory and anti-allergic drugs.
Morria is targeting three major inflammatory disease areas:
- Dermatology (contact dermatitis)- Respiratory (allergic rhinitis and cystic fibrosis)
- Gastro-intestinal inflammatory (IBD)
Pre-clinical and clinical (Phase II) development programs are currently underway.
- June 2010:
Morria Biopharmaceuticals Announces Positive Safety, Tolerability and Preliminary Efficacy Results for MRX-4 Phase II Study in Allergic Rhinitis at the EAACI Congress.
READ MORE - April 2010:
Morria Biopharmaceuticals Plc. Announces initiation of its Phase II Study In Contact Dermatitis Patients Using MRX6, A Novel Topical Anti-Inflammatory Drug.
READ MORE - August 2009:
Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug.
READ MORE